Physician profile
Jonathan M Desantis
NPI 1831197268
$38,530.27
in general payments reported to CMS, 2019-2025
34 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $12K · 2021: $8,160 · 2022: $822 · 2023: $1,384 · 2024: $767 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20,184.66 | 2019-2021 | |
| Esperion Therapeutics, INC. | $11,232.00 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $1,576.74 | 2019-2025 | |
| Amgen INC. | $900.77 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.82 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $488.34 | 2019-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $446.53 | 2019-2022 | |
| Boston Scientific Corporation | $430.92 | 2019-2023 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $403.29 | 2019-2025 | Breyanzi, Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $331.15 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $302.45 | 2021-2024 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $178.39 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $175.62 | 2019 | |
| Scpharmaceuticals INC. | $152.18 | 2023-2025 | |
| Medtronic, INC. | $138.91 | 2023 | Linq II |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112.89 | 2021-2024 | Verquvo |
| Pfizer INC. | $106.00 | 2019-2024 | |
| Azurity Pharmaceuticals, INC. | $86.71 | 2023 | Edarbyclor |
| Actelion Pharmaceuticals US, INC. | $82.90 | 2019-2025 | Uptravi |
| Lilly USA, LLC | $70.10 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Lexicon Pharmaceuticals, INC. | $57.96 | 2023-2024 | Inpefa |
| Baxter Healthcare | $43.15 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $40.03 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $37.27 | 2022-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.12 | 2022 | |
| Bridgebio Pharma, INC. | $20.50 | 2025 | Attruby |
| Agepha Pharma Fz LLC | $20.30 | 2025 | Lodoco |
| Philips North America LLC | $19.80 | 2020 | |
| Medicomp INC | $19.10 | 2022 | |
| Bardy Diagnostics, INC. | $14.91 | 2022 | |
| Ionis Pharmaceuticals, INC. | $13.70 | 2025 | Tryngolza |
| Janssen Scientific Affairs, LLC | $12.11 | 2023 | Xarelto |
| Irhythm Technologies, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Desantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.